

PB60385USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Monteith et al.

Serial No.: 10/564,191

Art Unit:

Filing Date:

Examiner:

For: Pharmaceutical Formulations Comprising Magnesium Stearate

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS


Sir:

In response to the Notification of Missing Requirements, mailed May 3, 2006, Applicants respectfully submit that no sequence listing is required. Applicants respectfully submit that the instant application does not include any peptide or nucleotide sequences. Accordingly, Applicants do not believe the submission of a Sequence Listing according to MPEP 2422.03 is required in the instant case.

Applicants have replied to the Notification of Missing Requirements by submission of a Declaration of the Inventors and applicable surcharges. Applicants respectfully request that the requirements for submissions related to sequence listings be withdrawn and the application be passed to the Examiner group for review.

In accordance with PTO requirements, a copy of the Notification of Missing Requirements is attached. The Office is invited to contact Applicants' representative, Scott Young, at (919) 483-8160 to discuss this matter further, if desired.

Respectfully submitted



J. Scott Young

Attorney for Applicants

Registration No. 45,582

Date: May 22 2006

GlaxoSmithKline

Five Moore Drive, PO Box 13398

Research Triangle Park

North Carolina 27709

Telephone: (919) 483-8160

Facsimile: (919) 483-7988